Marius Pharmaceuticals Expands Access of KYZATREX™ (testosterone undecanoate) to Department of Veterans Affairs (VA), Pledging Support for Proper Hormonal Balance Among Military Personnel
September 19, 2023 09:30 ET
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, is proud to announce the...
Marius Pharmaceuticals Partners with Smartway to Design and Manage the global Early Access Program for KYZATREX™ (testosterone undecanoate)
August 10, 2023 09:30 ET
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals (Marius) and Smartway Pharmaceuticals (Smartway) are pleased to announce their strategic partnership, aimed at addressing the...
Marius Pharmaceuticals Announces Launch of ReThink Testosterone, Disease-State Awareness Initiative for Patients
July 24, 2023 09:00 ET
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., July 24, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company specializing in therapies for hypogonadism or Testosterone Deficiency, is proud to...
Marius Pharmaceuticals Supports AXYS 2023 Virtual Family Conference, Spotlighting KYZATREX™ for XY Chromosome Variations, such as Klinefelter’s Syndrome
June 20, 2023 08:30 ET
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., June 20, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company specializing in therapies for hypogonadism or testosterone deficiency, announced today...
Marius Pharmaceuticals Announces Two Key Patents Related to KYZATREX™ in FDA Orange Book
June 09, 2023 10:00 ET
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., June 09, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company focused on therapies designed for hypogonadism or testosterone deficiency, announced...
CORRECTION -- Marius Pharmaceuticals Receives FDA Approval of KYZATREX™, an Oral Testosterone Replacement Therapy
September 21, 2022 11:08 ET
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., Sept. 21, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on August 2, 2022 by Marius Pharmaceuticals, please note that the correct number for reporting side...
Marius Announces Ambulatory Blood Pressure Results Published in the Journal of Clinical Hypertension with their new testosterone medication KYZATREX™
June 11, 2021 11:11 ET
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., June 11, 2021 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company focusing on therapies designed for hypogonadism, more commonly known as testosterone...
Marius Pharmaceuticals Receives PDUFA Date for KYZATREX® NDA for Treatment of Hypogonadism
March 11, 2021 10:00 ET
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) goal...
Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREX
January 28, 2021 10:00 ET
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a specialty pharmaceutical company focusing on treating conditions that are primarily associated with testosterone...